MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021

Rhea-AI Summary

MannKind Corporation (Nasdaq:MNKD) will announce its Q2 2021 financial results on August 11, 2021, at 5 PM ET. The conference call will feature insights from CEO Michael Castagna and CFO Steven B. Binder. Investors can access the call and the subsequent replay on MannKind's website. MannKind focuses on inhaled therapeutic products, notably the FDA-approved Afrezza, the only inhaled ultra-rapid-acting insulin available in the U.S. and Brazil. The company was founded in 1991 and is based in Westlake Village, California.

Positive

• MannKind's primary product, Afrezza, is the only inhaled ultra-rapid-acting mealtime insulin in the U.S.
• The upcoming conference call presents an opportunity for investors to gain insights into the company's performance and future outlook.

Negative

• None.

WESTLAKE VILLAGE, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 11, 2021.

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://investors.mannkindcorp.com/events-and-presentations Events & Presentations.  A replay will also be available on MannKind's website for 14 days.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra-rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit www.mannkindcorp.com to learn more.

MANNKIND CONTACT:
Rose Alinaya, Investor Relations
Phone: (818) 661-5000
Email: ir@mannkindcorp.com

FAQ

When will MannKind Corporation release its Q2 2021 financial results?

MannKind Corporation will release its Q2 2021 financial results on August 11, 2021, at 5 PM ET.

Who will present the financial results during the MannKind conference call?

The conference call will be presented by CEO Michael Castagna and CFO Steven B. Binder.

Where can I listen to the MannKind conference call?

The conference call can be accessed live via MannKind's website and will be available for replay for 14 days.

What is Afrezza and why is it significant for MannKind?

Afrezza is MannKind's first FDA-approved product and the only inhaled ultra-rapid-acting mealtime insulin available in the United States.